Black Diamond Therapeutics Inc. Common Stock (BDTX)
Stock · NASDAQ · Health Care
$1.71as of 10/16/2026
Price chart
Active signals
BDTX Signal Track Record
How signals performed across all stocks →What BDTX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 37 | +1.3% | 54% | September 16, 2026 |
| Bollinger Band Breakout | 27 | +1.3% | 52% | August 10, 2026 |
| Bollinger Band Breakdown | 14 | +0.1% | 50% | February 5, 2026 |
| 200-Day Moving Average TouchActive now | 12 | -4.7% | 42% | May 11, 2026 |
| Any 20-session window (baseline) | +0.2% | 50% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About BDTX
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 21
Fundamentals
- 1-day range
- $1.68$1.75
- Market cap
- $110.02M
- P/E (trailing)
- —
- P/E (forward)
- -1.72
- EPS (trailing)
- $-0.74
- Dividend yield
- —
- Beta
- 3.40
- Avg. volume
- 613.4K
How Black Diamond Therapeutics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 16, 2026 · via SEC EDGAR / Finnhub
Forecasts
7 analyst ratings
Black Diamond Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- BDTXBlack Diamond Therapeutics Inc. Common Stock$1.72▼ 1.15%Market cap $110.02MP/E —$1.6$4.94
- PTHSPelthos Therapeutics Inc. Common Stock$20.15▼ 0.54%Market cap $102.36MP/E —$18.19$37.5
- CGTXCognition Therapeutics Inc. Common Stock$0.73▼ 0.41%Market cap $101.13MP/E —$0.5501$2
- KLRSKalaris Therapeutics Inc. Common Stock$2▼ 8.68%Market cap $99.69MP/E —$2.35$11.88
- ENGNenGene Therapeutics Inc. Common Stock$1.67▼ 2.34%Market cap $120.58MP/E —$1.4$12.25
- ENTXEntera Bio Ltd. Ordinary Shares$2.68▼ 3.25%Market cap $139.00MP/E —$0.91$4.2
- CRDFCardiff Oncology Inc. Common Stock$0.9▼ 7.22%Market cap $74.71MP/E —$0.7566$3.31
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BDTX Black Diamond Therapeutics Inc. Common Stock | $110.02M | — | $1.72 | ▼ 1.15% | $1.6$4.94 |
| PTHS Pelthos Therapeutics Inc. Common Stock | $102.36M | — | $20.15 | ▼ 0.54% | $18.19$37.5 |
| CGTX Cognition Therapeutics Inc. Common Stock | $101.13M | — | $0.73 | ▼ 0.41% | $0.5501$2 |
| KLRS Kalaris Therapeutics Inc. Common Stock | $99.69M | — | $2 | ▼ 8.68% | $2.35$11.88 |
| ENGN enGene Therapeutics Inc. Common Stock | $120.58M | — | $1.67 | ▼ 2.34% | $1.4$12.25 |
| ENTX Entera Bio Ltd. Ordinary Shares | $139.00M | — | $2.68 | ▼ 3.25% | $0.91$4.2 |
| CRDF Cardiff Oncology Inc. Common Stock | $74.71M | — | $0.9 | ▼ 7.22% | $0.7566$3.31 |
P/E shows — for peers not currently carrying a live signal of their own.
Insider Activity
Insider Actions →- Prakash Raman · September 18, 2026 · Grant6.8K @ $1.93
- Ali Behbahani · September 18, 2026 · Grant7.7K @ $1.93
- Prakash Raman · June 19, 2026 · Grant7.9K @ $1.66
- Ali Behbahani · June 19, 2026 · Grant9.0K @ $1.66
Institutional Ownership
March 31, 2026
- Total shares held
- 36.81M
- Total value held
- $50.55M
- Institutional holders
- 101
- Unknown10.56M
- Unknown4.45M
- Unknown2.35M
- Unknown1.64M
- Unknown1.30M
- Unknown1.11M
- Unknown1.06M
- Unknown844.8K
- Unknown836.3K
- Unknown834.6K
See the full, filterable feed with live charts on the MarketWall dashboard.